Business - Monitor   

Ranbaxy gets FDA approval for Isotretinoin

MUMBAI: Ranbaxy Laboratories has received the approval from the U.S. Food and Drug Administration to manufacture and commercialise Isotretinoin Capsules USP, 30 mg, representing new dosage strength for Isotretinoin. Ranbaxy's wholly owned subsidiary, Ranbaxy Pharmaceuticals Inc (RPI) will market this product under the brand name Sotret. — Our Bureau

Printer friendly page  
Send this article to Friends by E-Mail

Business

News: Front Page | National | Southern States | Other States | International | Opinion | Business | Sport | Miscellaneous |
Advts: Classifieds | Employment | Obituary |

Stories in this Section

• ONGC PAT exceeds Rs. 10,000 cr.
• 160 p.c. final from IOC on expanded capital
• Profit taking on BSE
• Microsoft to release new software for PDAs
• Godrej Appliances' plans
• Nod for Parrys Confectionery to merge subsidiary
• Kotak Mahindra Bank to pay 21 p.c.
• India warns against Singapore issues at WTO
• Bullion rates
• Exchange rates
• Stock Market Index
• M&M launches new tractor
• OM Kotak premium income at Rs. 40 cr.
• Covansys' broadcast software for Encoda
• Ranbaxy gets FDA approval for Isotretinoin
• Wipro to market Chandrika soap
• Altair extends reach to SA region
• SPIC ads win RAPA award
• Rane Engine gets best supplier award
• Tyco Electronics's connector system

Copyright © 2003, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu